1
|
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer Sci 2024; 115:1273-1282. [PMID: 38287788 PMCID: PMC11006989 DOI: 10.1111/cas.16094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 01/01/2024] [Accepted: 01/14/2024] [Indexed: 01/31/2024] Open
Abstract
Durvalumab has been administered to patients with unresectable stage III non-small cell lung cancer (NSCLC). However, it remains unclear whether durvalumab benefits these patients with epidermal growth factor receptor (EGFR) mutation. We conducted a retrospective, multicenter study of patients with EGFR mutation who received chemoradiotherapy (CRT) between June 2018 and March 2021. We assessed patient characteristics, efficacy of durvalumab, and durvalumab safety before and after targeted therapy. We collected data on a total of 673 patients, of whom 401 (59.6%) underwent EGFR mutation testing. Fifty-one patients were EGFR positive and 311 were EGFR negative. In the EGFR-positive group, there were higher proportions of females, never-smokers, and patients with adenocarcinoma histology. Of the 51 patients in the positive group and 311 in the negative group who received CRT, 45 (88.2%) and 247 (79.4%) received durvalumab, with median progression-free survival of 23.0 and 24.2 months in the positive and negative groups, respectively (hazard ratio 1.03; 95% confidence interval: 0.64-1.67). The main adverse event was pneumonitis (positive group: 62.2%; 4.4% grade 3; negative group: 62.3%; 6.9% grade 3). No treatment-related deaths were observed. Of the 45 patients in the positive group who received durvalumab, 14 (31.1%) received targeted therapy after durvalumab at the data cutoff. One patient discontinued targeted therapy after developing pneumonitis. In patients with unresectable stage III NSCLC with EGFR mutation, durvalumab after CRT is potentially safe and effective. This may be a suitable treatment sequence for these patients.
Collapse
Affiliation(s)
- Kosuke Tsuji
- Department of Respiratory Medicine, Faculty of MedicineHokkaido UniversitySapporoJapan
| | - Hidenori Mizugaki
- Department of Respiratory Medicine, Faculty of MedicineHokkaido UniversitySapporoJapan
- Department of Advanced Medical DevelopmentThe Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan
- Department of Respiratory MedicineNHO Hokkaido Cancer CenterSapporoJapan
| | - Keiki Yokoo
- Department of Respiratory MedicineTeine Keijinkai HospitalSapporoJapan
| | - Maki Kobayashi
- Department of Respiratory MedicineMiyagi Cancer CenterNatoriJapan
| | - Yosuke Kawashima
- Department of Pulmonary MedicineSendai Kousei HospitalSendaiJapan
| | - Nozomu Kimura
- Department of Respiratory MedicineTohoku University Graduate School of MedicineSendaiJapan
| | - Hiroshi Yokouchi
- Department of Respiratory MedicineNHO Hokkaido Cancer CenterSapporoJapan
| | - Hajime Kikuchi
- Department of Respiratory MedicineObihiro‐Kousei General HospitalObihiroJapan
| | - Toshiyuki Sumi
- Department of Respiratory MedicineHakodate Goryoukaku HospitalHakodateJapan
| | - Yasutaka Kawai
- Department of Respiratory MedicineOji General HospitalTomakomaiJapan
| | - Kenta Kobashi
- Department of Pulmonary MedicineSteel Memorial Muroran HospitalMuroranJapan
| | - Ryo Morita
- Department of Respiratory MedicineAkita Kousei Medical CenterAkitaJapan
| | - Kenichiro Ito
- Department of Respiratory MedicineKKR Sapporo Medical CenterSapporoJapan
| | - Yasuo Kitamura
- Department of Respiratory MedicineKushiro City General HospitalKushiroJapan
| | - Hiroyuki Minemura
- Department of Pulmonary MedicineFukushima Medical University School of MedicineFukushimaJapan
| | - Keiichi Nakamura
- Department of Respiratory MedicineNational Hospital Organization Asahikawa Medical CenterAsahikawaJapan
| | - Mari Aso
- Department of Respiratory MedicineYamagata Prefectural Central HospitalYamagataJapan
| | - Osamu Honjo
- Department of Respiratory MedicineSapporo Minami‐Sanjo HospitalSapporoJapan
| | - Hisashi Tanaka
- Department of Respiratory Medicine, Graduate School of MedicineHirosaki UniversityHirosakiJapan
| | - Taichi Takashina
- Department of Respiratory MedicineIwamizawa Municipal General HospitalIwamizawaJapan
| | - Kyoji Tsurumi
- Department of Respiratory MedicineMiyagi Cancer CenterNatoriJapan
| | - Jun Sugisaka
- Department of Pulmonary MedicineSendai Kousei HospitalSendaiJapan
| | - Yoko Tsukita
- Department of Respiratory MedicineTohoku University Graduate School of MedicineSendaiJapan
| | - Satoshi Konno
- Department of Respiratory Medicine, Faculty of MedicineHokkaido UniversitySapporoJapan
| | - Satoshi Oizumi
- Department of Respiratory MedicineNHO Hokkaido Cancer CenterSapporoJapan
| |
Collapse
|
2
|
Ono H, Kawai Y, Ata S, Minamikawa H, Kurihara K, Tanaka S, Yoshida M. Synthesis of Multiblock Copolymer Composed of Biodegradable Poly(butylene succinate) and Poly(2-pyrrolidone): Impact of Each Block Length on the Mechanical Properties. Macromol Rapid Commun 2023:e2300155. [PMID: 37191110 DOI: 10.1002/marc.202300155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 04/21/2023] [Indexed: 05/17/2023]
Abstract
A series of multiblock copolymers comprising a systematic combination of biomass-originated and biodegradable poly(butylene succinate) (PBS) and poly(2-pyrrolidone) (PA4) units was synthesized with various mean degrees of polymerization (mDP) of each unit. Despite the inherent immiscibility of PBS and PA4, multiblock structure allowed us to mix the two components in the solution-cast films from solution. The mechanical properties of the cast films were highly dependent on the mDP of each unit, as demonstrated by tensile tests. The film of the copolymer with the lowest mDP of each unit (PBS: 17, PA4: 10) was transparent and exhibited extremely high elongation at break (> 400%) and high tensile stress (39.5 MPa) with strain hardening. The films with 50% or higher crystallinity were brittle and opaque, while a decrease in crystallinity could result in higher elongation, as revealed by wide-angle X-ray diffraction measurements. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Hideaki Ono
- Interdisciplinary Research Center for Catalytic Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan
| | - Yasutaka Kawai
- Interdisciplinary Research Center for Catalytic Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan
| | - Seisuke Ata
- Research Institute for Chemical Process Technology, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan
| | - Hiroyuki Minamikawa
- Interdisciplinary Research Center for Catalytic Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan
| | - Kazuma Kurihara
- Advanced Manufacturing Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 1-2-1 Higashi, Tsukuba, Ibaraki, 305-8564, Japan
| | - Shinji Tanaka
- Interdisciplinary Research Center for Catalytic Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan
| | - Masaru Yoshida
- Interdisciplinary Research Center for Catalytic Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan
| |
Collapse
|
3
|
Morinaga D, Asahina H, Ito S, Honjo O, Tanaka H, Honda R, Yokouchi H, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H. Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer. Cancer Med 2023. [PMID: 36999734 DOI: 10.1002/cam4.5889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2023] [Revised: 03/03/2023] [Accepted: 03/19/2023] [Indexed: 04/01/2023] Open
Abstract
PURPOSE Immune-checkpoint inhibitors (ICIs) are effective against advanced non-small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is unclear. This study was designed to address this question. METHODS We enrolled patients who received ICI monotherapy in Japan between December 2015 and December 2017; those ≥75 years of age comprised the elderly group. We compared the efficacy and safety of ICI monotherapy in elderly patients with those in younger patients and explored prognostic factors in elderly patients. RESULTS We enrolled 676 patients; 137 (20.3%) were assigned to the elderly group. The median age of the elderly and younger groups was 78 (range, 75-85) and 66 (range, 34-74) years. The median progression-free survival (4.8 months vs. 3.3 months, p = 0.1589) and median overall survival (12.3 months vs. 13.0 months, p = 0.5587) were similar between the elderly and younger groups. Multivariate analysis revealed that a significantly better OS in the elderly group was associated with better responses to first- or second-line ICI treatment (p = 0.011) and more immune-related adverse events (irAEs) (p = 0.02). IrAEs that led to ICI discontinuation occurred in 34 of 137 patients (24.8%) in the elderly group, and their survival was significantly higher than that in those who did not have irAEs. CONCLUSION ICI is also effective in elderly NSCLC patients, and treatment discontinuation due to irAEs may be a good prognostic marker.
Collapse
Affiliation(s)
- Daisuke Morinaga
- Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hajime Asahina
- Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Shotaro Ito
- Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Osamu Honjo
- Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan
| | - Hisashi Tanaka
- Department of Respiratory Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan
| | - Ryoichi Honda
- Department of Respiratory Medicine, Asahi General Hospital, Asahi, Japan
| | - Hiroshi Yokouchi
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
| | - Keiichi Nakamura
- Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan
| | - Kei Takamura
- Department of Respiratory Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan
| | - Fumihiro Hommura
- Department of Respiratory Medicine, Sapporo City General Hospital, Sapporo, Japan
| | - Yasutaka Kawai
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan
| | - Kenichiro Ito
- Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan
| | - Noriaki Sukoh
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan
| | - Keiki Yokoo
- Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Japan
| | - Ryo Morita
- Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan
| | - Toshiyuki Harada
- Department of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan
| | - Taichi Takashina
- Department of Respiratory Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan
| | - Tomohiro Goda
- Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Japan
| | - Hirotoshi Dosaka-Akita
- Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Japan
- Research Division of Cancer Immunotherapy, Hokkaido University Hospital, Japan
| | - Hiroshi Isobe
- Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan
| |
Collapse
|
4
|
Yamamoto E, Kawai Y, Takakura K, Kimura M, Murayama H, Matsueda H, Otsuki S, Sakata H, Tokunaga M. Cover Feature: Convenient Unsymmetrical Disulfane Synthesis: Basic Zeolite‐Catalyzed Thiol‐Disulfane Exchange Reaction (ChemCatChem 22/2021). ChemCatChem 2021. [DOI: 10.1002/cctc.202101589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Eiji Yamamoto
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Yasutaka Kawai
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Kei Takakura
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Moemi Kimura
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Haruno Murayama
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Hironobu Matsueda
- Fine Synthesis Technical Div. 1 DIC Corporation 18 Higashifukashiba Kamisu Ibaraki 314-0193 Japan
| | - Shujiro Otsuki
- Fine Synthesis Technical Div. 1 DIC Corporation 18 Higashifukashiba Kamisu Ibaraki 314-0193 Japan
| | - Hiroshi Sakata
- Fine Synthesis Technical Div. 1 DIC Corporation 18 Higashifukashiba Kamisu Ibaraki 314-0193 Japan
| | - Makoto Tokunaga
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| |
Collapse
|
5
|
Kuroda K, Tsuji M, Saito E, Kawamura K, Ono T, Tokioka K, Kawai Y. Hyperacute postprocedural high platelet reactivity: a novel predictor for in-hospital adverse events in acute coronary syndrome with prasugrel loading. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Postprocedural High platelet reactivity (HPR) seems to associate long term adverse cardiovascular events, mainly intrastent thrombosis. However, the relationship between hyper-acute postprocedural HPR with prasugrel loading and clinical outcomes in acute coronary syndrome (ACS) is still unclear. Moreover, factors contributing HPR in ACS with prasugrel loading are also unknown.
Purpose
This study aimed to assess the impact of hyper-acute postprocedural HPR with prasugrel loading on clinical outcomes in ACS during hospitalization, as well as to define appropriate cut-off values and identify contributing factors of HPR.
Methods
We performed a single-centre, retrospective observational study that enrolled 207 patients who underwent emergent PCI for ACS with prasugrel loading. The P2Y12reaction unit (PRU) value was measured immediately after PCI with the VerifyNow System. The primary endpoint was major adverse cardiac events (MACE, defined as the composite of death, myocardial infarction, stroke, heart failure, ventricular arrhythmia needing defibrillation).
Results
Mean patient age (standard deviation) was 70.5 (±13.0) years, 78.7% were male, and average time from prasugrel intake to PRU calculation was 98.3 (±49.1) min. During a mean hospital stay of 15.9 (±9.3) days, there were 34 in-hospital MACE (16.4%) and 10 deaths (4.8%). Thrombosis events, didn't stand out and mechanical complications, such as cardiac rupture and cardiac tamponade occupies most of cardiovascular death which occurred before 10 days on admission. PRU was significantly higher in MACE group than Non-MACE group (279±65 vs 227±72, p<0.001 respectively). The ROC curve analysis of PRU for discriminating significant in-hospital MACE showed the cut off value of 293 (sensitivity:52.9%, specificity:83.2% [AUC=0.709, p<0.0001]). 47patients (29.4%) were thus categorized as HPR (PRU>293) immediately after emergent PCI. Kaplan-Meyer curve showed MACE events occurred in HPR group than non-HPR group (38.2% vs 10.0%, p<0.001). Multiple cox analysis demonstrated that HPR was independent predictors of MACE in patients with ACS underwent PCI (OR 5.416, 95% CI 2.157–13.598, p<0.0001). Multiple logistic regression model showed female sex, low haemoglobin value, and large mean platelet volume were independent predictors of HPR.
Conclusion
PRU was significantly higher in MACE group, and appropriate cut-off value of HPR in this study was 293. HPR was independent predictor of MACE during hospitalization, however thrombosis event was not significant. Evidence of clinical impact with postprocedural HPR within 120 minutes after prasugrel loading is scarce. This study shows post-procedural HPR, even without sufficient time after prasugrel intake, can be a useful predictive marker of adverse events during hospitalization.
Funding Acknowledgement
Type of funding sources: None. PRU between Non-MACE and MACE groupKaplan-Meyer curve
Collapse
Affiliation(s)
- K Kuroda
- Okayama City Hospital, Okayama, Japan
| | - M Tsuji
- Okayama City Hospital, Okayama, Japan
| | - E Saito
- Okayama City Hospital, Okayama, Japan
| | | | - T Ono
- Okayama City Hospital, Okayama, Japan
| | - K Tokioka
- Okayama City Hospital, Okayama, Japan
| | - Y Kawai
- Okayama City Hospital, Okayama, Japan
| |
Collapse
|
6
|
Ono T, Miyoshi T, Ueki Y, Kuroda K, Saito E, Tsuji M, Kawamura K, Tokioka K, Ohe T, Kawai Y. Cardio-ankle vascular index is useful screening method to detect obstructive coronary artery disease in asymptomatic diabetes patients with subclinical atherosclerosis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Patients with diabetes mellitus are at very high risk for obstructive coronary artery disease; however, invasive coronary angiography is not allowed to apply in all patients. Cardio-ankle vascular index (CAVI), a marker of arterial stiffness has been reported to reflect atherosclerotic burden.
Purpose
To assess the diagnostic performance of CAVI vs. coronary calcium score for detecting obstructive coronary artery disease determined by Coronary CT angiography (CCTA) in asymptomatic diabetes patients.
Methods
During May 2015 to December 2019, 816 patients with diabetes mellitus were evaluated. First, intima-media thickness of carotid artery was measured in all subjects. Then, patients with intima-media thickness over 11mm underwent CAVI. Finally, 209 patients who have one or more cardiovascular risk factors other than diabetes mellitus were enrolled (68±11 years, 68% men). Patients were excluded if they had a disorder of the kidney, a prior history of coronary artery revascularization, atrial fibrillation, LV ejection fraction <50%, ABI <0.9 or allergy to contrast. Diagnostic performance of CAVI was evaluated with coronary stenosis >50% by CCTA.
Results
CAVI, Agatston score, and intima-media thickness of carotid artery were 9.2±1.3, 396±621 and 2.0±0.7mm, respectively. CAVI was significantly correlated with age (r=0.530, p<0.001), coronary artery calcification (r=0.182, p=0.008), and intima-media thickness of carotid artery (r=0.195, p=0.005). Among them, 108 patients (48%) had coronary stenosis. CAVI, Agatston score and intima-media thickness of carotid artery in patients with coronary stenosis were higher than that without coronary stenosis, respectively (9.8±1.1 vs 8.5±1.0, p<0.001, 526±676 vs. 255±525, p=0.001, 2.2±0.7 vs. 1.8±0.6, p<0.001). The ROC curve analysis of CAVI for discriminating coronary stenosis showed that the sensitivity 75.0% and specificity 77.2% at the cut off value of 9.23 (AUC=0.812, p<0.001). Contrastingly, diagnostic performance of coronary calcium score and intima-media thickness of carotid artery were less than CAVI (sensitivity: 91.7%, specificity: 56.4%, AUC=0.753, p<0.05 vs. CAVI, sensitivity: 68.5%, specificity: 59.4%, AUC=0.663, p<0.05 vs. CAVI). Multivariate logistic analysis demonstrated that CAVI was significantly associated with coronary stenosis (OR=4.133, p<0.001) after adjustment of conventional risk factors, although coronary calcium score was not correlated with coronary stenosis.
Conclusion
CAVI could be informative to select patients having obstructive coronary artery disease in asymptomatic diabetes patients with thick intima-media thickness.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- T Ono
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - T Miyoshi
- Okayama University, Department of Cardiovascular Medicine, Okayama, Japan
| | - Y Ueki
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Kuroda
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - E Saito
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - M Tsuji
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Kawamura
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Tokioka
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - T Ohe
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - Y Kawai
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| |
Collapse
|
7
|
Tsuji M, Kuroda K, Saito E, Kawamura K, Ono T, Tokioka K, Ohe T, Kawai Y. Impact of high platelet reactivity on left ventricular remodeling in patients with acute coronary syndrome. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
Previous studies demonstrated that high platelet reactivity (HPR) predicts future cardiovascular death and coronary events in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). However, few studies have focused on the impact of HPR on left ventricular remodeling (LVR) and each echocardiographic parameter.
Purpose
The purpose of this study was to investigate the impact of HPR in ACS patients on LVR and changes in echocardiographic volume indexes and LV ejection fraction.
Methods
This is a retrospective cohort study of prospectively collected data in a single center that enrolled patients who underwent emergency PCI for ACS including STEMI and NSTEMI with prasugrel loading. The primary outcome of the study was LVR associated with HPR. Secondary endpoints were changes in indexed LVESV, LVEDV, LVEF, E/e' and LAVI between baseline and follow-up. The P2Y12 reaction unit (PRU) value in response to prasugrel was assessed by the VerifyNow P2Y12 assay. Blood samples were collected once per procedure immediately after PCI. LVR index was calculated as the relative change in LVEDV observed at follow-up compared with baseline. LVR was defined as a relative increase in LVEDV ≥20%, measured at follow-up visit compared with the baseline value before discharge.
Results
A total of 196 ACS patients who underwent emergency PCI between January 2016 and July 2020 were enrolled in the study. The mean age of the study population was 69.9 years, and 76.0% were male. On echocardiography at follow up visit of mean duration of 7.0±4.0 months, LVR was found in 38 patients (19.4%). The optimal cutoff for PRU associated with increased LVR assessed by receiver-operating characteristic curve analysis was 245.5 (AUC: 0.656; 95% CI: 0.564 to 0.749; p=0.003). On the basis of this cutoff, HPR was found in 82 patients (42.1%) and the prevalence of LVR was significantly higher in the HPR group compared to the non-HPR group (30.5% vs. 11.4%; p=0.001). Multiple Cox regression analysis showed that HPR was an independent predictor of LVR (OR 4.22, 95% CI 1.83–9.71, p=0.001). In addition, Δ% EDV and Δ% ESV increased in the HPR group, and decreased in the non-HPR group with significant differences (5.8±32.6% vs. −8.0±26.2% in Δ% EDV; p=0.002, 2.0±37.5% vs. −13.3±33.0% in Δ% ESV; p=0.004, respectively). Δ%EF, Δ%E/e', Δ%LAVI were numerically improved in the non-HPR group compared with the HPR group, but this difference did not reach statistical significance.
Conclusion
In patients with ACS, HPR defined as PRU ≥246 immediately after emergency PCI was an independent predictor of LVR in the chronic phase.
Funding Acknowledgement
Type of funding sources: None. Predictors of the presence of LVRChanges (Δ%) of LVEDV and LVESV
Collapse
Affiliation(s)
- M Tsuji
- Okayama City Hospital, Okayama, Japan
| | - K Kuroda
- Okayama City Hospital, Okayama, Japan
| | - E Saito
- Okayama City Hospital, Okayama, Japan
| | | | - T Ono
- Okayama City Hospital, Okayama, Japan
| | - K Tokioka
- Okayama City Hospital, Okayama, Japan
| | - T Ohe
- Okayama City Hospital, Okayama, Japan
| | - Y Kawai
- Okayama City Hospital, Okayama, Japan
| |
Collapse
|
8
|
Yamamoto E, Kawai Y, Takakura K, Kimura M, Murayama H, Matsueda H, Otsuki S, Sakata H, Tokunaga M. Convenient Unsymmetrical Disulfane Synthesis: Basic Zeolite‐Catalyzed Thiol‐Disulfane Exchange Reaction. ChemCatChem 2021. [DOI: 10.1002/cctc.202101092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Eiji Yamamoto
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Yasutaka Kawai
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Kei Takakura
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Moemi Kimura
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Haruno Murayama
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| | - Hironobu Matsueda
- Fine Synthesis Technical Div. 1 DIC Corporation 18 Higashifukashiba Kamisu Ibaraki 314-0193 Japan
| | - Shujiro Otsuki
- Fine Synthesis Technical Div. 1 DIC Corporation 18 Higashifukashiba Kamisu Ibaraki 314-0193 Japan
| | - Hiroshi Sakata
- Fine Synthesis Technical Div. 1 DIC Corporation 18 Higashifukashiba Kamisu Ibaraki 314-0193 Japan
| | - Makoto Tokunaga
- Department of Chemistry Graduate School of Science Kyushu University 744 Motooka Nishi-ku Fukuoka 819-0395 Japan
| |
Collapse
|
9
|
Ohhara Y, Kojima T, Honjo O, Yamada N, Sato T, Kunisaki M, Takamura K, Takashina T, Sukoh N, Tanaka H, Kawai Y, Fujita Y, Sugaya F, Hommura F, Harada T, Honda R, Kinoshita I, Amano T, Satoshi O, Akita H. MO30-2 Prognostic factors for non-small cell lung cancer patients with brain metastases (HOT 1701). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). Thorac Cancer 2021; 12:2113-2121. [PMID: 34076966 PMCID: PMC8287008 DOI: 10.1111/1759-7714.14048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 05/17/2021] [Accepted: 05/18/2021] [Indexed: 01/20/2023] Open
Abstract
Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label randomized phase II trial, was designed to assess the benefit of maintenance therapy in patients with ED‐SCLC who responded to induction therapy. Methods Patients with histologically‐ or cytologically‐confirmed ED‐SCLC were included and were treated with an induction therapy of four cycles of cisplatin (60 mg/m2 on day 1) plus CPT‐11 (60 mg/m2 on days 1, 8, and 15) every four weeks. After induction therapy, patients who had nonprogressive disease were randomized to receive either maintenance CPT‐11 (60 mg/m2 on days 1 and 8) every three weeks, or AMR (35 mg/m2 on days 1–3) every three weeks. Results A total of 34 patients were enrolled; 20 patients had progressive disease or received incomplete induction chemotherapy. Finally, 14 patients were randomly assigned to receive CPT‐11 (n = 7) or AMR (n = 7). This study was terminated prematurely because of low patient accrual. The overall objective response rate was 73%, the median PFS was 5.7 months (95% confidence interval [CI]: 3.6–11.8), and the median overall survival was 20.1 months (95% CI: 13.7–not reached). No statistically significant difference in progression‐free survival (PFS) were noted between patients treated with CPT‐11 and those treated with AMR. There were no treatment‐related deaths in this study. Conclusions Maintenance therapy with CPT‐11 or AMR after induction therapy might be effective in some patients.
Collapse
Affiliation(s)
- Hisashi Tanaka
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - Yukihiro Hasegawa
- Department of Respiratory Medicine, Aomori Prefectural Central Hospital, Aomori, Japan
| | - Yuka Fujita
- Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan
| | - Atsushi Nakamura
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
| | - Eiki Kikuchi
- First Department of Medicine, Hokkaido University Hospital, Sapporo, Japan
| | - Yasutaka Kawai
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan
| | - Toshiyuki Harada
- Department of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan
| | - Naomi Watanabe
- Department of Respiratory Medicine, Sunagawa City Medical Center, Sunagawa, Japan
| | - Hiroshi Yokouchi
- Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.,Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
| | - Kazuhiro Usui
- Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan
| | - Ryota Saito
- Department of Respiratory Medicine, Tohoku University School of Medicine, Sendai, Japan
| | - Hiroshi Watanabe
- Department of Respiratory Medicine, Saka General Hospital, Shiogama, Japan
| | - Tomomi Masuda
- Department of Respiratory Medicine, Gunma University, Maebashi, Japan
| | - Tatsuro Fukuhara
- Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan
| | - Keita Kudo
- Department of Medical Oncology and Respiratory Medicine, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan
| | - Ryoichi Honda
- Department of Respiratory Medicine, Asahi General Hospital, Chiba, Japan
| | - Satoshi Oizimi
- First Department of Medicine, Hokkaido University Hospital, Sapporo, Japan.,Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
| | - Makoto Maemondo
- Division of Pulmonary Medicine, Allergy, and Rheumatology, Iwate Medical University Faculty of Medicine Graduate School of Medicine Morioka, Iwate, Japan
| | - Akira Inoue
- Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan
| | - Naoto Morikawa
- Division of Pulmonary Medicine, Allergy, and Rheumatology, Iwate Medical University Faculty of Medicine Graduate School of Medicine Morioka, Iwate, Japan.,Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan
| |
Collapse
|
11
|
Ito S, Asahina H, Honjo O, Tanaka H, Honda R, Oizumi S, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H. Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902). Lung Cancer 2021; 156:12-19. [PMID: 33872943 DOI: 10.1016/j.lungcan.2021.04.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 03/19/2021] [Accepted: 04/10/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Limited information is available on the appropriate treatment duration of immune checkpoint inhibitors (ICIs). We aimed to identify candidates who would benefit from ICI discontinuation after one year of treatment for metastatic non-small cell lung cancer (NSCLC). MATERIALS AND METHODS This retrospective multi-institutional observational study examined medical records of all consecutive patients with advanced or recurrent NSCLC, who started ICI monotherapy at 15 institutions in Japan between December 2015 and December 2017. Patients who received initial ICI therapy for >1 year without progressive disease were defined as the long-term treatment (LT) group; others were defined as the non-long-term treatment (NLT) group. Primary outcomes included the prognostic factors in the LT group, whereas secondary outcomes included efficacy of ICI rechallenge, safety, and survival outcomes in the overall population. RESULTS In total, 676 patients were enrolled, and 114 (16.9 %) were assigned to the LT group. The median time interval from the start of initial ICI administration to data cutoff was 34.3 months (range, 24.1-47.8); thus, all surviving patients were followed-up for at least 2 years from the start of initial ICI. Median progression-free survival (PFS) was longer in the LT than in the NLT group (33.6 months vs. 2.7 months; p < 0.001). On multivariate analysis, significantly better PFS was associated with smoking (hazard ratio [HR]=0.36, p = 0.04), and complete response (CR; HR=uncomputable, p < 0.001) in the LT group. Thirty-seven patients (5.5 %) received ICI rechallenge, including 10 in the LT group. Among patients receiving rechallenge treatment, the median PFS was 2.2 months, with no difference between the LT and NLT groups. CONCLUSIONS In the LT group, smoking and achieving CR were significantly associated with better PFS. Since rechallenge treatment was not effective, careful consideration is required for discontinuing ICI. However, these prognostic factors are helpful in considering candidates for ICI discontinuation. TRIAL REGISTRATION UMIN ID, UMIN000041403.
Collapse
Affiliation(s)
- Shotaro Ito
- Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hajime Asahina
- Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
| | - Osamu Honjo
- Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan
| | - Hisashi Tanaka
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - Ryoichi Honda
- Department of Respiratory Medicine, Asahi General Hospital, Asahi, Japan
| | - Satoshi Oizumi
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
| | - Keiichi Nakamura
- Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan
| | - Kei Takamura
- Department of Respiratory Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan
| | - Fumihiro Hommura
- Department of Respiratory Medicine, Sapporo City General Hospital, Sapporo, Japan
| | - Yasutaka Kawai
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan
| | - Kenichiro Ito
- Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan
| | - Noriaki Sukoh
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan
| | - Keiki Yokoo
- Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Japan
| | - Ryo Morita
- Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan
| | - Toshiyuki Harada
- Department of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan
| | - Taichi Takashina
- Department of Respiratory Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan
| | - Tomohiro Goda
- Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hirotoshi Dosaka-Akita
- Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hiroshi Isobe
- Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan
| | | |
Collapse
|
12
|
Watanabe T, Matsumoto Y, Amamizu H, Morosawa S, Ohyama K, Sugisawa J, Tsuchiya S, Sato K, Shindo T, Nishimiya K, Watanabe-Asaka T, Hayashi M, Kawai Y, Shimokawa H. A novel therapeutic approach for coronary inflammation and lymphatic vessels using non-invasive low-intensity pulsed ultrasound in a porcine model with DES-induced coronary hyperconstricting responses. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The coronary adventitia harbors lymphatic vessels (LVs). We previously demonstrated that coronary adventitial inflammation and LV dysfunction play important roles in the pathogenesis of coronary artery spasm, including drug-eluting stent (DES)-induced coronary hyperconstricting responses, in pigs and humans. However, a direct therapeutic approach to the coronary adventitia remains to be developed.
Purpose
In this study, we aimed to examine whether our novel and non-invasive therapy with low-intensity pulsed ultrasound (LIPUS) ameliorates DES-induced coronary hyperconstricting responses, and if so, what mechanisms are involved.
Methods
An everolimus-eluting stent (EES) was implanted into the left anterior descending (LAD) coronary artery in normal male pigs. They were randomly assigned to the LIPUS or the sham therapy groups. After EES implantation, in the LIPUS group, LIPUS (32 cycles, 193 mW/cm2) was applied to the heart at 3 different levels (proximal and distal stent edges and middle portion of the stent) through X-ray fluoroscopy for 20 min at each level for every other day for 2 weeks (6 days in total) (Fig. 1A, B). The sham therapy group was treated in the same manner but without LIPUS. At 4 weeks after the procedure, we performed coronary angiography to examine coronary vasoconstricting responses to intracoronary serotonin in vivo. Finally, stented coronary vessels were harvested for immunohistochemistry of vasa vasorum (vWF), LVs (LYVE-1), vascular inflammation (CD68-positive macrophages and IL-1β expression), vascular endothelial growth factor A (VEGF-A, angiogenesis marker), VEGF-C and VEGF receptor 3 (VEGFR3, lymphangiogenesis markers).
Results
Coronary vasoconstricting responses to intracoronary serotonin at the DES edges in the LAD were significantly enhanced in the sham group but were significantly suppressed in the LIPUS group, while those responses were comparable at the non-DES implanted left circumflex (LCx) coronary artery between the 2 groups (Fig. 1C, D). In addition, in vivo lymph transport speed was significantly faster in the LIPUS group than in the sham group (Fig. 1E–G). In histological analysis, the number of LVs was significantly increased in the LIPUS group compared with the sham group, whereas those of CD68 and IL-1β expressions were significantly reduced in the LIPUS group compared with the sham group. In contrast, the density of vasa vasorum was comparable between the 2 groups. Mechanistically, the extents of VEGF-C and VEGFR3 expressions were increased in the LIPUS group, whereas that of VEGF-A was comparable between the 2 groups (Fig. 1G–K). Importantly, there were significant correlations among the LV-related changes and enhanced coronary vasoconstricting responses.
Conclusion
These results provide the first evidence that the LIPUS therapy ameliorates DES-induced coronary hyperconstricting responses in pigs in vivo through structural and functional alterations of LVs (Fig. 1L).
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Watanabe
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Y Matsumoto
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - H Amamizu
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Morosawa
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - K Ohyama
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - J Sugisawa
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Tsuchiya
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - K Sato
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - T Shindo
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - K Nishimiya
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - T Watanabe-Asaka
- Tohoku Medical and Pharmaceutical University, Physiology, Sendai, Japan
| | - M Hayashi
- Tohoku Medical and Pharmaceutical University, Physiology, Sendai, Japan
| | - Y Kawai
- Tohoku Medical and Pharmaceutical University, Physiology, Sendai, Japan
| | - H Shimokawa
- Tohoku University Graduate School of Medicine, Sendai, Japan
| |
Collapse
|
13
|
Ono T, Miyoshi T, Ohno Y, Ueki Y, Kuroda K, Kawamura K, Tokioka K, Ohe T, Kawai Y. Cardio-ankle vascular index as an arterial stiffness marker improves on cardiovascular events by adding to framingham risk score. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The cardio-ankle vascular index (CAVI) is a non-invasive measurement that evaluates arterial stiffness using the analysis of oscillometric waveform during cuff-Inflation. Several studies reported that CAVI is associated with cardiovascular risk factors, while the clinical prognostic value of CAVI as a surrogate marker of atherosclerosis has not been fully elucidated. Meanwhile, the Framingham risk score (FRS) is an established marker of cardiovascular outcomes.
Purpose
To investigate whether adding CAVI to Framingham risk score improves the prediction of cardiovascular events.
Methods
This prospective observational study included consecutive 422 patients with cardiovascular risk factors but without known coronary artery disease (69±8 years, 63% men). CAVI was measured by the oscillometric method with VaSera vascular screening system. Patients with atrial fibrillation, left ventricular ejection fraction <50%, both ABI<0.9, severe valvular diseases, or hemodialysis were excluded. Primacy outcomes were cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure and revascularization.
Results
During a median follow-up of 3.1 years, cardiovascular events occurred in 12.8% (3.3%, 15.7%, and 19.1% in the low, intermediate and high-risk group of stratification by FRS, respectively). The ROC curve analysis for discriminating cardiovascular events showed that the AUC of CAVI added to Framingham risk score was the highest compared to Framingham risk score and CAVI alone (CAVI added to Framingham risk score: AUC 66.9, 95% CI 59.6–74.2, Framingham risk score alone: AUC 61.5, 95% CI 53.8–69.1, CAVI alone: AUC 62.3, 95% CI 54.1–70.6). The logistic regression analysis demonstrated that CAVI and Framingham risk score were independent predictors of cardiovascular events (CAVI: OR 1.381, 95% CI 1.164–1.597, p=0.004, Framingham risk score: OR 1.135, 95% CI 1.044–1.225, p=0.007). Next, when logistic regression analysis was performed simultaneously on Framingham risk factor and CAVI, CAVI was an independent predictor of cardiovascular events (OR 1.347, 95% CI 1.124–1.569, p=0.009). Furthermore, in the likelihood ratio test, CAVI added to Framingham risk score significantly improved the cardiovascular event prediction ability than Framingham risk factor alone. Next, when patients with intermediate risk (n=217) were divided into two groups based on CAVI of 9.0, the Kaplan-Meier estimate showed that events occurred more frequently in higher CAVI group (9.3% and 29.1%, log-rank, P=0.009) and the C-statistic was 0.662. Multiple Cox analysis showed that, in the intermediate risk group, CAVI was an independent predictor of primary outcomes (HR 1.387 per 1 index, 95% CI 1.081–1.779, p=0.010).
Conclusion
The measurement of CAVI could be a useful predictor for cardiovascular events. In addition, the combination of CAVI and Framingham risk score could improve the predictability compared to the Framingham risk score alone.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Ono
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - T Miyoshi
- Okayama University, Department of Cardiovascular Medicine, Okayama, Japan
| | - Y Ohno
- Kawasaki University of Medical Welfare, Department of Medical Technology, Kurashiki, Japan
| | - Y Ueki
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Kuroda
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Kawamura
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Tokioka
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - T Ohe
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - Y Kawai
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| |
Collapse
|
14
|
Takimoto Sato M, Ikezawa Y, Sato M, Suzuki A, Kawai Y. Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report. Mol Clin Oncol 2020; 13:43-47. [PMID: 32499913 PMCID: PMC7265227 DOI: 10.3892/mco.2020.2045] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2019] [Accepted: 04/28/2020] [Indexed: 11/06/2022] Open
Abstract
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare type of lung cancer, accounting for 3% of all lung cancers. The prognosis is poor and the standard therapy has not been well established. Herein, we report a case of advanced LCNEC of the lung that responded to nivolumab. The patient was a 62-year old man with stage IVB LCNEC of the lung. The disease progressed following the administration of second-line chemotherapy, and he was treated with nivolumab 3 mg/kg as the third-line treatment. Although treatment was ceased after two cycles due to interstitial pneumonia, the disease remained stable for approximately six months under observation. There was no other adverse event related to nivolumab. Following patient mortality from tumor progression, PD-L1 expression was observed to be negative (tumor proportion score <1%) by a re-examination of the primary biopsy specimen. The case herein suggests that nivolumab may be a possible treatment option for LCNEC.
Collapse
Affiliation(s)
- Michiko Takimoto Sato
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Hokkaido 0538506, Japan
| | - Yasuyuki Ikezawa
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Hokkaido 0538506, Japan
| | - Mineyoshi Sato
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Hokkaido 0538506, Japan
| | - Akira Suzuki
- Department of Pathology, Oji General Hospital, Tomakomai, Hokkaido 0538506, Japan
| | - Yasutaka Kawai
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Hokkaido 0538506, Japan
| |
Collapse
|
15
|
Wakasa M, Kawai Y, Kajinami K. P104 Prognostic value of Circulating Amino Acids (AAs) in Patients with Idiopathic Dilated Cardiomyopathy (DCM). Eur Heart J 2020. [DOI: 10.1093/ehjci/ehz872.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Backgrounds Circulating levels of some amino acids are significantly decreased in heart failure patients. However, relationship between their levels and cardiac function remains unclear. We therefore examined association between amino acid levels and cardiac function as prognostic predictor in DCM patients.
Methods
Consecutive 59 patients with DCM (M/F: 46/13, mean age: 59 years) were enrolled. We measured 25 kinds of plasma AA concentration, derivative of reactive oxygen metabolites (d-ROMs) as marker of oxidative stress, and washout rate of Tc-99m Sestamibi (WOR) as function of mitochondria and LVEF as LV function parameters. The occurrence of rehospitalization for cardiac events or cardiac death were followed during mean 1101 days (13-2626).
Results
Histidine, arginine and Fischer ratio (FR) showed a significant positive association with LVEF (p < 0.05). Threonine and asparagine showed a significant negative association with WOR (P < 0.05). Histidine and arginine showed a significant negative association with levels of d-ROMs (p < 0.05).Rehospitalization for cardiac events and cardiac death were recorded in 16 patients (27%) and 6 patients (10%), respectively. Kaplan-Meier curves analysis showed similar trend of rehospitalization in subjects with lower FR and those with higher values. However, cardiac death in subjects with lower FR was observed more frequently as compared to those with higher values (22.2% vs 5.3% p < 0.05).
ConclusionsThe plasma FR could be a novel prognostic biomarker in DCM patients.
Collapse
Affiliation(s)
- M Wakasa
- Kanazawa Medical University, Ishikawa, Japan
| | - Y Kawai
- Kanazawa Medical University, Ishikawa, Japan
| | - K Kajinami
- Kanazawa Medical University, Ishikawa, Japan
| |
Collapse
|
16
|
Baba K, Tanaka H, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Fujibayashi K, Oda M, Wakasa M, Takano S, Kuzume Y, Saeki Y, Sawaguchi J, Fujita W, Saito R, Kawai Y, Kajinami K. P3648Plasma glutamate are increased in non-smoker patients with vasospastic angina pectoris and associated with plasma cystine and antioxidant capacity. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Endothelial dysfunction of the coronary arteries caused by oxidative stress plays an important role in the pathogenesis of vasospastic angina pectoris (VSAP). Glutamate, a non-essential amino acid, exerts endothelial dysfunction by oxidative stress production through N-methyl-D-aspartate receptor activation. Besides oxidative stress, decrease of antioxidant may be responsible for endothelial dysfunction. Glutathione (GSH), an important antioxidant, is synthesized from imported cystine through the cystine/glutamate antiporter system (XC-) in association with the export of glutamate. Glutamate also competitively inhibits cystine import into the endothelial cells through the XC-leading to GSH depletion. Thus the extracellular glutamate and cystine are crucial for the intracellular redox status. However, it remains unclear whether glutamate and/or cystine are implicated in the pathogenesis of VSAP. As smoking induces powerful oxidant stresses in the whole body, we investigated plasma glutamate, cystine, oxidative stress markers and antioxidant capacity in non-smoker patients with VSAP.
Methods and results
Sixty-two consecutive non-smoker patients suspected having VSAP were performed coronary angiograms (CAG). Forty-nine patients who did not show any significant coronary stenosis (<50%) were performed the intracoronary acetylcholine provocation test. Patients were categorized into the VSAP-positive group (n=27) and the VSAP-negative group (n=22) on the basis of test results. Blood samples were collected from the femoral sheath before the CAG. Plasma glutamate, cystine, nitrotyrosine (NT), reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) were measured. The levels of plasma glutamate and cystine in the VSAP-positive group were significantly higher than those in the VSAP-negative group (59.8±25.7 vs 43.5±18.7 nmol/L, p=0.0054, and 35.3±14.2 nmol/L vs 25.2±9.1 nmol/L, p=0.0018, respectively). The levels of plasma glutamate showed significant and positive association with the levels of plasma cystine (r=0.40, p=0.005). There were no significant differences in the levels of NT and d-ROMs as oxidative stress markers, and BAP as an antioxidant capacity between the two groups, respectively. However, the levels of plasma glutamate showed significant and negative association with BAP values (r=−0.3, p=0.038).
Conclusions
Plasma levels of glutamate were increased in non-smoker patients with VSAP and positively associated with plasma cystine levels and negatively associated with antioxidant capacity, suggesting that plasma glutamate modulate plasma cystine levels and antioxidant capacity through the XC- inhibition, and could be a novel risk factor of VSAP.
Collapse
Affiliation(s)
| | - M Oda
- Kanazawa Medical University, Uchinada, Japan
| | - M Wakasa
- Kanazawa Medical University, Uchinada, Japan
| | - S Takano
- Kanazawa Medical University, Uchinada, Japan
| | - Y Kuzume
- Kanazawa Medical University, Uchinada, Japan
| | - Y Saeki
- Kanazawa Medical University, Uchinada, Japan
| | - J Sawaguchi
- Kanazawa Medical University, Uchinada, Japan
| | - W Fujita
- Kanazawa Medical University, Uchinada, Japan
| | - R Saito
- Kanazawa Medical University, Uchinada, Japan
| | - Y Kawai
- Kanazawa Medical University, Uchinada, Japan
| | - K Kajinami
- Kanazawa Medical University, Uchinada, Japan
| |
Collapse
|
18
|
Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Namba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nakamura K, Ito H. 1407Drug effect of luseogliflozin and voglibose on heart failure with preserved ejection fraction in diabetic patients: a multicenter randomized-controlled trial. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Recent randomized, placebo-controlled trial in patients with type 2 diabetes demonstrated that the sodium-glucose cotransporter 2 inhibitors reduced mortality, cardiovascular events and hospitalization for heart failure. However, those trials were not specialized design to investigate the effect of sodium-glucose cotransporter 2 inhibitors in patients with heart failure, in particular with heart failure with preserved ejection fraction.
Purpose
The aim of this study was to evaluate the drug efficacy of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, compared with voglibose, an alpha-glucosidase inhibitor, using brain natriuretic peptide (BNP) in type 2 diabetes patients with heart failure with preserved ejection fraction.
Methods
This study was a prospective, multicenter, open-label, randomized-controlled trial, comparing luseogliflozin 2.5 mg once daily or voglibose 0.2 mg three times daily in patients with type 2 diabetes suffering from heart failure with preserved ejection fraction (left ventricular ejection fraction >45% and BNP ≥35 pg/ml2) in a 1:1 randomization fashion. Randomization was undertaken using a computer-generated random sequence web response system. The primary outcome was the difference from baseline in BNP after 12 weeks of treatment between two drugs. The key secondary outcomes were the change from baseline in left ventricular ejection fraction and E/e' in echocardiographic parameters, body weight, glycohemoglobin level after 12 weeks of treatment. The safety outcomes included the incidence of major adverse cardiovascular events, hypoglycemic adverse events, and urinary tract infection.
Results
Between December 2015 and September 2018, 173 patients from 16 hospitals and clinics have been included in this study. Of those, 83 patients were assigned to receive luseogliflozin and 82 to receive voglibose. There was no significant difference in the reduction in the BNP concentration after 12 weeks from baseline between the two groups; the ratio of the average values at week 12 to the baseline value was 0.91 in the luseoglifllzin group as compared with 0.98 in the voglibose group (percent change, −9.0% vs. −1.9%, ratio of change with luseogliflozin vs. voglibose, 0.93; 95% confidence interval, 0.78 to 1.10; p=0.26). The key secondary outcomes including left ventricular ejection fraction, E/e', body weight, glycohemoglobin level and the safety outcomes did not differ significantly between the two groups.
Conclusions
In type 2 diabetes patients with heart failure with preserved ejection fraction, the administration of luseogliflozin did not lead to a significant reduction in the BNP concentration than that of voglibose. Left ventricular ejection fraction, E/e', body weight and glycohemoglobin level after 12 weeks of treatment, comparing with at baseline did not differ significantly between the two groups. (UMIN Clinical Trial Registry number, UMINehz748.005618395)
Acknowledgement/Funding
Novartis
Collapse
Affiliation(s)
- K Ejiri
- Okayama University, Cardiovascular Medicine, Okayama, Japan
| | - T Miyoshi
- Okayama University, Cardiovascular Medicine, Okayama, Japan
| | - H Kihara
- Kihara Cardiovascular Clinic, Internal Medicine, Asahikawa, Japan
| | - Y Hata
- Minamino Cardiovascular Hospital, Cardiology, Hachioji, Japan
| | - T Nagano
- Iwasa Hospital, Internal Medicine, Gifu, Japan
| | - A Takaishi
- Mitoyo General Hospital, Cardiology, Kanonji, Japan
| | - H Toda
- Okayama East Neurosurgery Hospital, Internal Medicine, Okayama, Japan
| | - S Namba
- Okayama Rosai Hospital, Cardiology, Okayama, Japan
| | - Y Nakamura
- Specified Clinic of Soyokaze Cardiovascular Medicine and Diabetes Care, Cardiovascular Medicine, Matsuyama, Japan
| | - S Akagi
- Akaiwa Medical Association Hospital, Internal Medicine, Akaiwa, Japan
| | - S Sakuragi
- Iwakuni Clinical Center, Cardiovascular Medicine, Iwakuni, Japan
| | - T Minagawa
- Minagawa Cardiovascular Clinic, Internal Medicine, Gifu, Japan
| | - Y Kawai
- Okayama City Hospital, Cardiovascular Medicine, Okayama, Japan
| | - K Nakamura
- Okayama University, Cardiovascular Medicine, Okayama, Japan
| | - H Ito
- Okayama University, Cardiovascular Medicine, Okayama, Japan
| |
Collapse
|
19
|
Kuroda K, Gentaro S, Kawamura K, Ono T, Tokioka K, Kawai Y, Tohru O. P4634Acute-phase high platelet reactivity with prasugrel loading is correlated with clinical outcomes during hospitalization in acute coronary syndrome. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Introduction
Although high platelet reactivity (HPR) seems to be associated with adverse cardiovascular events after percutaneous coronary intervention (PCI), the relationship between post-procedure HPR with prasugrel loading and clinical outcomes in acute coronary syndrome (ACS) is still unclear. Moreover, factors contributing to HPR in ACS with prasugrel loading are also unknown.
Purpose
This study aimed to assess the impact of post-procedure HPR with prasugrel loading on clinical outcomes in ACS during hospitalization, as well as to define appropriate cut-off values and identify factors contributing to HPR.
Methods
We performed a single-centre, retrospective observational study that enrolled 132 patients who underwent emergent PCI for ACS with prasugrel loading. The P2Y12 reaction unit (PRU) value was measured immediately after PCI with the VerifyNowR System. The primary endpoint was major adverse cardiac events (MACE, defined as the composite of death, myocardial infarction, stroke, heart failure, ventricular arrhythmia needing defibrillation).
Results
Mean patient age (standard deviation) was 70.7 (±12.5) years, 76% were male, and average time from prasugrel intake to PRU calculation was 101 (±48.8) min. During a mean hospital stay of 15.4 (±8.0) days, there were 22 (16%) MACE events and 6 (4%) deaths. The post-procedure PRU value was 241±66. HPR was significantly higher in MACE group than non-MACE group [287 (±55) vs 232 (±64), p<0.001]. The ROC curve analysis of PRU for discriminating significant in-hospital MACE showed a cut off value of 293 (sensitivity: 64%, specificity: 84% [AUC=0.764, p<0.0001]). Thus, 33 patients (25%) were found to have HPR (PRU>293) immediately after emergent PCI. Kaplan-Meier curve analysis showed MACE events occurred more frequently in the HPR group than in the non-HPR group (42% vs 8%, log rank p<0.001). Multiple Cox regression analysis showed that peak creatine phosphokinase >3,000 U/L and HPR were independent predictors of MACE in patients with ACS who underwent PCI (OR 4.96, 95% CI 1.86–13.26, p=0.001, and OR 7.52, 95% CI 2.73–20.7, p<0.0001, respectively). HPR was significantly correlated with age, female sex, and reference lumen short diameter (pre-dilation) used in PCI.
Conclusion
HPR was significantly associated with adverse event during hospitalization in ACS patients. Female patients with large culprit lesion diameter were more likely to have HPR. Appropriate cut-off value of HPR in this study was 293. HPR in early-phase of ACS with prasugrel loading is a useful predictor of adverse events during hospitalization.
Collapse
Affiliation(s)
- K Kuroda
- Okayama City Hospital, Okayama, Japan
| | - S Gentaro
- Okayama City Hospital, Okayama, Japan
| | | | - T Ono
- Okayama City Hospital, Okayama, Japan
| | - K Tokioka
- Okayama City Hospital, Okayama, Japan
| | - Y Kawai
- Okayama City Hospital, Okayama, Japan
| | - O Tohru
- Okayama City Hospital, Okayama, Japan
| |
Collapse
|
20
|
Ohhara Y, Kojima T, Honjo O, Yamada N, Sato T, Kunisaki M, Takamura K, Takashina T, Sukoh N, Tanaka H, Kawai Y, Fujita Y, Sugaya F, Hommura F, Harada T, Ryoichi H, Kinoshita I, Amano T, Oizumi S, Akita H. Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Ohwada G, Minakuchi S, Sato Y, Kondo H, Nomura T, Tsuboi A, Hong G, Itoh Y, Kawai Y, Kimoto S, Gunji A, Suzuki A, Suzuki T, Kimoto K, Hoshi N, Saita M, Yoneyama Y, Sato Y, Morokuma M, Okazaki J, Maeda T, Nakai K, Ichikawa T, Nagao K, Fujimoto K, Murata H, Kurogi T, Yoshida K, Nishimura M, Nishi Y, Murakami M, Hosoi T, Hamada T. Subjective Evaluation of Denture Adhesives: A Multicenter Randomized Controlled Trial. JDR Clin Trans Res 2019; 5:50-61. [PMID: 30975019 DOI: 10.1177/2380084419837607] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
INTRODUCTION Many reports show that denture adhesives improve the retention and stability of dentures. However, few randomized controlled trials have examined the effects of denture adhesives. OBJECTIVE This 10-center randomized controlled trial with parallel groups involving 200 edentulous patients wearing complete dentures aimed to evaluate the effects of short-term use of cream and powder denture adhesives. METHODS Patients were allocated into 2 cream- and powder-type adhesive groups and 1 control group. Intervention groups were treated with the 2 adhesives (1 each), and the control group received saline solution. Adhesive or control was applied to the denture-mucosal surface for 4 d, and data at baseline and after day 4 of intervention (i.e., 8 meals) were obtained. Patient satisfaction was evaluated with a 100-mm visual analog scale. Oral health-related quality of life was measured with the Japanese version of the Oral Health Impact Profile for Edentulous Patients. Perceived chewing ability was evaluated by a questionnaire regarding ease of chewing and swallowing food. Between-group comparisons were performed with Kruskal-Wallis tests with the Mann-Whitney U test adjusted by Bonferroni correction. Within-group comparisons of pre- and postintervention measurements were performed with the Wilcoxon signed-rank test. Intention-to-treat analysis was also performed. RESULTS Between-group comparisons showed no significant differences for general satisfaction or Oral Health Impact Profile for Edentulous Patients. However, significant differences in satisfaction with various denture functions with cream- and powder-type adhesives were seen in pre- and postintervention comparisons (P < 0.05). Significant differences were also observed for perceived chewing ability of hard foods (P < 0.05). CONCLUSION These results suggest that although denture adhesives do not invariably improve denture function, they do affect subjective evaluations and possibly chewing of hard foods. Therefore, the effects of denture adhesive use are insufficient to resolve any fundamental dissatisfaction with dentures ( ClinicalTrials.gov NCT01712802 ). KNOWLEDGE TRANSFER STATEMENT The results of this study suggest that denture adhesives should be applied under certain conditions; however, an appropriate diagnosis is important before application. These practice-based data provide information to establish evidence-based guidelines for applying denture adhesives.
Collapse
Affiliation(s)
- G Ohwada
- The Japan Denture Care Society.,Gerodontology and Oral Rehabilitation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Minakuchi
- The Japan Denture Care Society.,Gerodontology and Oral Rehabilitation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Y Sato
- The Japan Denture Care Society.,Gerodontology and Oral Rehabilitation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - H Kondo
- The Japan Denture Care Society.,Department of Prosthodontics and Oral Implantology, School of Dentistry, Iwate Medical University, Morioka, Japan
| | - T Nomura
- The Japan Denture Care Society.,Department of Prosthodontics and Oral Implantology, School of Dentistry, Iwate Medical University, Morioka, Japan
| | - A Tsuboi
- The Japan Denture Care Society.,Division of Community Oral Health Science, Department of Community Medical Supports, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan
| | - G Hong
- The Japan Denture Care Society.,Liaison Center for Innovative Dentistry, Graduate School of Dentistry, Tohoku University, Sendai, Japan
| | - Y Itoh
- The Japan Denture Care Society.,Division of Aging and Geriatric Dentistry, Graduate School of Dentistry, Tohoku University, Sendai, Japan
| | - Y Kawai
- The Japan Denture Care Society.,Department of Removable Prosthodontics, School of Dentistry, Nihon University, Matsudo, Japan
| | - S Kimoto
- The Japan Denture Care Society.,Department of Removable Prosthodontics, School of Dentistry, Nihon University, Matsudo, Japan
| | - A Gunji
- The Japan Denture Care Society.,Department of Removable Prosthodontics, School of Dentistry, Nihon University, Matsudo, Japan
| | - A Suzuki
- The Japan Denture Care Society.,Department of Removable Prosthodontics, Graduate School of Dentistry, Nihon University, Matsudo, Japan
| | - T Suzuki
- The Japan Denture Care Society.,Section of Oral Prosthetic Engineering, Tokyo Medical and Dental University, Tokyo, Japan
| | - K Kimoto
- The Japan Denture Care Society.,Division of Prosthodontics and Oral Rehabilitation, Department of Oral Function and Restoration, Graduate School of Dentistry, Kanagawa Dental University, Yokosuka, Japan
| | - N Hoshi
- The Japan Denture Care Society.,Division of Prosthodontics and Oral Rehabilitation, Department of Oral Function and Restoration, Graduate School of Dentistry, Kanagawa Dental University, Yokosuka, Japan
| | - M Saita
- The Japan Denture Care Society.,Division of Prosthodontics and Oral Rehabilitation, Department of Oral Function and Restoration, Graduate School of Dentistry, Kanagawa Dental University, Yokosuka, Japan
| | - Y Yoneyama
- The Japan Denture Care Society.,Department of Removable Prosthodontics, School of Dental Medicine, Tsurumi University, Yokohama, Japan
| | - Y Sato
- The Japan Denture Care Society.,Department of Removable Prosthodontics, School of Dental Medicine, Tsurumi University, Yokohama, Japan
| | - M Morokuma
- The Japan Denture Care Society.,Department of Removable Prosthodontics, School of Dental Medicine, Tsurumi University, Yokohama, Japan
| | - J Okazaki
- The Japan Denture Care Society.,Department of Removable Prosthodontics and Occlusion, Osaka Dental University, Osaka, Japan
| | - T Maeda
- The Japan Denture Care Society.,Department of Removable Prosthodontics and Occlusion, Osaka Dental University, Osaka, Japan
| | - K Nakai
- The Japan Denture Care Society.,Department of Removable Prosthodontics and Occlusion, Osaka Dental University, Osaka, Japan
| | - T Ichikawa
- The Japan Denture Care Society.,Department of Oral and Maxillofacial Prosthodontics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima City, Japan
| | - K Nagao
- The Japan Denture Care Society.,Department of Oral and Maxillofacial Prosthodontics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima City, Japan
| | - K Fujimoto
- The Japan Denture Care Society.,Department of Oral and Maxillofacial Prosthodontics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima City, Japan
| | - H Murata
- The Japan Denture Care Society.,Department of Prosthetic Dentistry, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Japan
| | - T Kurogi
- The Japan Denture Care Society.,Department of Prosthetic Dentistry, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Japan
| | - K Yoshida
- The Japan Denture Care Society.,Department of Prosthetic Dentistry, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Japan
| | - M Nishimura
- The Japan Denture Care Society.,Department of Oral and Maxillofacial Prosthodontics, Field of Oral and Maxillofacial Rehabilitation, Course for Advanced Therapeutic, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima City, Japan
| | - Y Nishi
- The Japan Denture Care Society.,Department of Oral and Maxillofacial Prosthodontics, Field of Oral and Maxillofacial Rehabilitation, Course for Advanced Therapeutic, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima City, Japan
| | - M Murakami
- The Japan Denture Care Society.,Denture Prosthodontic Restoration, Advanced Dentistry Center, Kagoshima University Medical and Dental Hospital, Kagoshima City, Japan
| | - T Hosoi
- The Japan Denture Care Society.,School of Dental Medicine, Tsurumi University, Yokohama, Japan
| | - T Hamada
- The Japan Denture Care Society.,Hiroshima University, Hiroshima City, Japan
| |
Collapse
|
22
|
Goda T, Kinoshita I, Oizumi S, Nakano K, Harada T, Kawai Y, Sakakibara-Konishi J, Yokouchi H, Morikawa N, Yamada N, Yamazaki S, Sugawara S, Asahina H, Amano T, Hatanaka Y, Matsuno Y, Nishihara H, Isobe H, Nishimura M, Dosaka-Akita H. A prospective observational study of HER2 alterations in NSCLCs: HOT1303-A. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Amamizu H, Matsumoto Y, Morosawa S, Ohyama K, Uzuka H, Hirano M, Sugisawa J, Tsuchiya S, Nishimiya K, Hayashi M, Kawai Y, Shimokawa H. 2435Important roles of cardiac lymphatic vessels in the regulation of coronary vasomotion after DES implantation in pigs in vivo. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.2435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- H Amamizu
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - Y Matsumoto
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - S Morosawa
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - K Ohyama
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - H Uzuka
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - M Hirano
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - J Sugisawa
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - S Tsuchiya
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - K Nishimiya
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| | - M Hayashi
- Tohoku Pharmaceutical University Hospital, Physiology, Sendai, Japan
| | - Y Kawai
- Tohoku Pharmaceutical University Hospital, Physiology, Sendai, Japan
| | - H Shimokawa
- Tohoku University Graduate School of Medicine, Cardiovascular Medicine, Sendai, Japan
| |
Collapse
|
24
|
Ono T, Miyoshi T, Ohno Y, Kuroda K, Shokoku G, Yamamoto K, Tokioka K, Kawai Y, Ito H, Ohe T. P4786Incremental prognostic value of cardio-ankle vascular index as an arterial stiffness marker in patients with intermediate risk for cardiovascular disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Ono
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - T Miyoshi
- Okayama University, Department of Cardiovascular Medicine, Okayama, Japan
| | - Y Ohno
- Okayama University, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Kuroda
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - G Shokoku
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Yamamoto
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - K Tokioka
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - Y Kawai
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| | - H Ito
- Okayama University, Department of Cardiovascular Medicine, Okayama, Japan
| | - T Ohe
- Okayama City Hospital, Department of Cardiovascular Medicine, Okayama, Japan
| |
Collapse
|
25
|
Uraguchi D, Kawai Y, Sasaki H, Yamada K, Ooi T. Allenedicarboxylate as a Stereochemically Labile Electrophile for Chiral Organic Base-catalyzed Stereoselective Michael Addition. CHEM LETT 2018. [DOI: 10.1246/cl.180031] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Daisuke Uraguchi
- Institute of Transformative Bio-Molecules (WPI-ITbM) and Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho D2-1, Chikusa, Nagoya, Aichi 464-8601, Japan
| | - Yasutaka Kawai
- Institute of Transformative Bio-Molecules (WPI-ITbM) and Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho D2-1, Chikusa, Nagoya, Aichi 464-8601, Japan
| | - Hitoshi Sasaki
- Institute of Transformative Bio-Molecules (WPI-ITbM) and Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho D2-1, Chikusa, Nagoya, Aichi 464-8601, Japan
| | - Kohei Yamada
- Institute of Transformative Bio-Molecules (WPI-ITbM) and Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho D2-1, Chikusa, Nagoya, Aichi 464-8601, Japan
| | - Takashi Ooi
- Institute of Transformative Bio-Molecules (WPI-ITbM) and Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho D2-1, Chikusa, Nagoya, Aichi 464-8601, Japan
- CREST, Japan Science and Technology Agency (JST), Nagoya University, Nagoya, Aichi 464-8601, Japan
| |
Collapse
|
26
|
Ogawa T, Kimoto S, Nakashima Y, Furuse N, Ono M, Furokawa S, Okubo M, Yamaguchi H, Kawai Y. Differences in pain thresholds elicited by intraoral electrical stimuli between individuals with and without diabetes mellitus. J Oral Rehabil 2018; 45:235-239. [DOI: 10.1111/joor.12601] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2017] [Indexed: 11/30/2022]
Affiliation(s)
- T. Ogawa
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - S. Kimoto
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - Y. Nakashima
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - N. Furuse
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - M. Ono
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - S. Furokawa
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - M. Okubo
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - H. Yamaguchi
- Department of Anesthesiology; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - Y. Kawai
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| |
Collapse
|
27
|
Kawai Y, Asahina H, Ikezawa Y, Oizumi S, Ogi T, Watanabe M, Amano T, Dosaka-Akita H, Isobe H, Nishimura M. P2.01-005 A Randomized Phase II Trial of Erlotinib vs S-1 in Patients with NSCLC as Third- or Fourth-Line Therapy (HOT1002). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M. A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002). Cancer Chemother Pharmacol 2017; 80:955-963. [PMID: 28905108 DOI: 10.1007/s00280-017-3432-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Accepted: 09/08/2017] [Indexed: 10/18/2022]
Abstract
PURPOSE A high proportion of patients with wild-type EGFR non-small cell lung cancer (NSCLC) receive third-line therapy and beyond, with no prospective randomized trials addressing the issue. This study aimed to select the most suitable regimen as a third- or fourth-line therapy for wild-type EGFR NSCLC. METHODS This multicenter, randomized phase II study in Japan included patients with recurrent or advanced NSCLC with wild-type or unknown EGFR, who progressed after two or three previous chemotherapies. The patients were randomly assigned to erlotinib (150 mg/day, days 1-21) or S-1 (80-120 mg/day, days 1-14) every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was disease control rate (DCR). The secondary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), toxicity, and quality of life (QOL). RESULTS From 2011 to 2016, 37 patients were randomly assigned to receive erlotinib (E arm, n = 19) and S-1 (S arm, n = 18). This study was terminated prematurely because of poor patient accrual. DCR/ORR were 42.1%/15.8% in the E arm and 66.7%/16.7% in the S arm. Median PFS/OS were 1.6 months/8.0 months in the E arm and 3.3 months/12.2 months in the S arm. In both groups, the most commonly reported grade 3-4 toxicities were fatigue, anorexia, and nausea. One grade 5 pneumonitis occurred in the S arm. No significant difference was seen in QOL. CONCLUSIONS S-1 as a third- or fourth-line therapy for wild-type EGFR NSCLC showed numerically better clinical outcomes than erlotinib. CLINICAL TRIAL REGISTRATION NO UMIN000005308.
Collapse
Affiliation(s)
- Yasuyuki Ikezawa
- First Department of Medicine, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.,Department of Respiratory Medicine, Oji General Hospital, 3-4-8 Wakakusa-cho, Tomakomai, Hokkaido, 053-8506, Japan
| | - Hajime Asahina
- First Department of Medicine, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
| | - Satoshi Oizumi
- First Department of Medicine, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.,Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, 003-0804, Japan
| | - Masahiro Watanabe
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, 003-0804, Japan
| | - Kei Takamura
- Department of Respiratory Medicine, Obihiro-Kosei General Hospital, 1 West 6, North 8, Obihiro, Hokkaido, 080-0016, Japan
| | - Yasutaka Kawai
- Department of Respiratory Medicine, Oji General Hospital, 3-4-8 Wakakusa-cho, Tomakomai, Hokkaido, 053-8506, Japan
| | - Noriyuki Yamada
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, 003-0804, Japan.,Department of Respiratory Medicine, Iwamizawa Municipal General Hospital, 2 West 7, 9-jo, Iwamizawa, Hokkaido, 068-8555, Japan
| | - Toshiyuki Harada
- Center for Respiratory Diseases, JCHO Hokkaido Hospital, 3-18, 8-chome, Nakanoshima 1-jo, Sapporo, Hokkaido, 062-8618, Japan
| | - Ichiro Kinoshita
- Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Yuka Fujita
- Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, 7-4048 Hanasaki-cho, Asahikawa, Hokkaido, 070-8644, Japan
| | - Eisaku Miyauchi
- Department of Respiratory Medicine, Tohoku University School of Medicine, 1-1 Seiryou-cho, Aoba-ku, Sendai, Miyagi, 980-8574, Japan
| | - Takahiro Ogi
- Department of Respiratory Medicine, Obihiro-Kosei General Hospital, 1 West 6, North 8, Obihiro, Hokkaido, 080-0016, Japan
| | - Toraji Amano
- Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Megumi Furuta
- First Department of Medicine, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Jun Sakakibara-Konishi
- First Department of Medicine, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Hiroshi Nishihara
- Department of Translational Pathology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Hirotoshi Dosaka-Akita
- Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Hiroshi Isobe
- Department of Respiratory Medicine, KKR Sapporo Medical Center, 3-40, 6-chome, Hiragishi 1-jo, Toyohira-ku, Sapporo, Hokkaido, 062-0931, Japan
| | - Masaharu Nishimura
- First Department of Medicine, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | | |
Collapse
|
29
|
Ono T, Miyoshi T, Ohno Y, Syokoku G, Yamamoto K, Tokioka K, Kawai Y, Ito H. P5453Cardio-ankle vascular index, a novel parameter of subclinical atherosclerosis predicts prognosis in patients at high risk for cardiovascular disease. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Aoki H, Kawai Y, Nakanishi H, Tskeuchi M. P4354Glycer-AGEs is associated with the severity of cardiac function of diabetic cardiomyopathy (DbCM). Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Shido K, Kojima K, Hozawa A, Ogishima S, Minegishi N, Kawai Y, Tamiya G, Tanno K, Yamasaki K, Aiba S, Suzuki Y, Nagasaki M. 503 Genome-wide association study identifies novel susceptibility loci for tanning ability in Japanese population. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Ogata H, Saito M, Tsuneizumi M, Kutomi G, Hosoya K, Kawai Y, Sugizaki K, Katsumata N, Senuma K, Kitabatake T, Suda M, Uomori T, Miura K, Kurata M, Nitta Y, Yonemoto N, Matsuoka J. Abstract P5-11-03: Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients – according to recent multi-institutional double-blind randomized clinical research on the AC regimen. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-11-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
<Background>
The information presented herein extends our recent study of TTT (Trial for Triplet Antiemetic Therapy).
One of our main clinical questions has been whether a 2nd generation serotonin receptor antagonist (5-HT3ra) would be superior to 1st generation 5-HT3ra when administering triplet antiemetic therapy for the prevention of chemotherapy induced nausea & vomiting (CINV), since a prior Japanese trial demonstrated palonosetron to be superior to granisetron for controlling the delayed phase of CINV induced by highly emetogenic chemotherapy (HEC) and to doublet antiemetic therapy including dexamethasone for anthracycline and cyclophosphamide containing regimens (AC).
<Objectives>
In this study, we assessed the efficacies of 1st and 2nd generation 5-HT3ra agents for use as triplet antiemetic therapy for AC, by monitoring CINV, focusing especially daily CR in the delayed phase.
<Material and method>
Between 2012 and 2015, 491 women with breast cancer receiving AC were recruited from 11 institutions in Japan, and randomly assigned to either single-dose palonosetron (0.75mg) or granisetron (40μg/kg) prior to chemotherapy on day 1, both with dexamethasone (9.9 mg intravenously) and aprepitant (125mg orally) on day 1 followed by additional doses (80mg orally) on days 2 and 3. Age, institution and habitual alcohol intake were used as stratification factors. The primary endpoint was a complete response (CR). Statistical analysis was done by Mantel-Haenszel Method. This trial was registered with UMIN000007882.
<Results>
All 491 patients were included in efficacy analyses (ITT): 246 patients in the palonosetron group and 245 in the granisetron group. We previously reported that the difference in CR during the delayed phase, i.e. 24 hours after the administration of AC, did not reach statistical significance (53.8% vs 58.5%) in MASCC 2016. However, daily CR in the palonosetron group was much higher than that in the granisetron group after 48 hours.
<Conclusions>
Palonosetron showed better efficacy in controlling CINV during the late period of the delayed phase, i.e. 48 hours after AC administration, than granisetron as triplet antiemetic therapy for AC.
<Considerations>
The pattern of CINV reportedly shows two peaks including an acute phase caused by serotonin and a delayed phase caused by substance P, though the pattern of CINV with triplet antiemetic therapy administration might be different if the suppression of each of these peaks were to be achieved more efficiently. CINV may not be divided into two phases in the future, or the borderline area between the acute and delayed phases may require revision. The analysis of the late period of the delayed phase was ad hoc in this trial. However, when conducting studies related to CINV, it might be worthwhile to revise the borderline area between the two phases of CINV to facilitate elucidating the mechanisms underlying this potentially debilitating side effect of chemotherapy.
Citation Format: Ogata H, Saito M, Tsuneizumi M, Kutomi G, Hosoya K, Kawai Y, Sugizaki K, Katsumata N, Senuma K, Kitabatake T, Suda M, Uomori T, Miura K, Kurata M, Nitta Y, Yonemoto N, Matsuoka J. Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients – according to recent multi-institutional double-blind randomized clinical research on the AC regimen [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-03.
Collapse
Affiliation(s)
- H Ogata
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Saito
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Tsuneizumi
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - G Kutomi
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Hosoya
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - Y Kawai
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Sugizaki
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - N Katsumata
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Senuma
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - T Kitabatake
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Suda
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - T Uomori
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - K Miura
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - M Kurata
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - Y Nitta
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - N Yonemoto
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| | - J Matsuoka
- Toho University Ohmori Medical Center, Tokyo, Japan; Juntendo University, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Sapporo Medical University, Sapporo, Japan; Tottori University, Yonago, Japan; Tokyo Medical University, Tokyo, Japan; Ohme Municipal General Hospital, Ohme, Japan; Nippon Medical School Musashi Kosugi Hospital, Tokyo, Japan; Juntendo University Shizuoka Branch Hospital, Izunagaoka, Japan; Juntendo University Urayasu Hospital, Urayasu, Japan; Juntendo University Nerima Hospital, Tokyo, Japan
| |
Collapse
|
33
|
Kawai Y, Nagai Y, Ogawa E, Kondo H. Japanese Society for Laboratory Hematology flow cytometric reference method of determining the differential leukocyte count: external quality assurance using fresh blood samples. Int J Lab Hematol 2016; 39:202-222. [DOI: 10.1111/ijlh.12607] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 10/25/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Y. Kawai
- The Standardization Subcommittee for Blood Cell Counting of the Japanese Society for Laboratory Hematology; Tokyo Japan
- International University of Health & Welfare; Sanno Hospital; Tokyo Japan
| | - Y. Nagai
- The Standardization Subcommittee for Blood Cell Counting of the Japanese Society for Laboratory Hematology; Tokyo Japan
- Nihon Kohden Corporation; IVD Operations; Tokyo Japan
- Kansai University of Health Sciences; Osaka Japan
| | - E. Ogawa
- The Standardization Subcommittee for Blood Cell Counting of the Japanese Society for Laboratory Hematology; Tokyo Japan
- Nippon Becton Dickinson Company, Ltd; BD, Biosciences; Tokyo Japan
| | - H. Kondo
- The Standardization Subcommittee for Blood Cell Counting of the Japanese Society for Laboratory Hematology; Tokyo Japan
- Kansai University of Health Sciences; Osaka Japan
| |
Collapse
|
34
|
Irie H, Ito K, Kataoka Y, Fujioka Y, Oguchi K, Shimamura T, Kawai Y, Sagara T, Shibata Y, Araki H, Haruma T, Hashimoto A, Matsuo K, Utsugi T, Iwasawa Y. TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32658-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Matsuyama H, Yamamoto Y, Kawai Y, Fujita Y, Hamamoto Y, Matsuyama K, Otori T, Haginaka J. Prediction of total clearance by UGT1A and ABC genes polymorphisms can predict tumor response and proteinuria in axitinib treatment for advanced renal cell carcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Hosonaga M, Arima Y, Sato E, Yamada K, Kaise H, Kawai Y, Teraoka S, Saya H, Ishikawa T. Intratumoral heterogeneity of HER2 expression is relevant to breast cancer malignancy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Brereton M, McCafferty R, Marsden K, Kawai Y, Etzell J, Ermens A. Recommendation for standardization of haematology reporting units used in the extended blood count. Int J Lab Hematol 2016; 38:472-82. [DOI: 10.1111/ijlh.12563] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Accepted: 07/11/2016] [Indexed: 11/29/2022]
Affiliation(s)
- M. Brereton
- Central Manchester University Hospitals NHS Foundation Trust; Manchester UK
| | | | - K. Marsden
- Royal Hobart Hospital; Hobart Tas. Australia
| | - Y. Kawai
- International University of Health & Welfare; Sanno Affiliate Hospital; Tokyo Japan
- Japanese Society for Laboratory Haematology; Tokyo Japan
| | - J. Etzell
- Sutter Health Shared Laboratory; Livermore CA USA
| | - A. Ermens
- Amphia hospital; Breda The Netherlands
| | | |
Collapse
|
38
|
Keng TB, De La Salle B, Bourner G, Merino A, Han JY, Kawai Y, Peng MT, McCafferty R. Standardization of haematology critical results management in adults: an International Council for Standardization in Haematology, ICSH, survey and recommendations. Int J Lab Hematol 2016; 38:457-71. [PMID: 27426950 DOI: 10.1111/ijlh.12526] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 04/18/2016] [Indexed: 01/28/2023]
Abstract
INTRODUCTION These recommendations are intended to develop a consensus in the previously published papers as to which parameters and what values should be considered critical. A practical guide on the standardization of critical results management in haematology laboratories would be beneficial as part of good laboratory and clinical practice and for use by laboratory-accrediting agencies. METHODS A working group with members from Europe, America, Australasia and Asia was formed by International Council for Standardization in Haematology. A pattern of practice survey of 21 questions was distributed in 2014, and the data were collected electronically by Survey Monkey. The mode, or most commonly occurring value, was selected as the threshold for the upper and lower alert limits for critical results reporting. RESULTS A total of 666 laboratories submitted data to this study and, of these, 499 submitted complete responses. Full blood count critical results alert thresholds, morphology findings that trigger critical result notification, critical results alert list, notification process and maintenance of critical results management protocol are described. This international survey provided a snapshot of the current practice worldwide and has identified the existence of considerable heterogeneity of critical results management. CONCLUSION The recommendations in this study represent a consensus of good laboratory practice. They are intended to encourage the implementation of a standardized critical results management protocol in the laboratory.
Collapse
Affiliation(s)
- T B Keng
- Sullivan Nicolaides Pathology, Indooroopilly, QLD, Australia.
| | - B De La Salle
- UK National External Quality Assessment Scheme for Haematology, West Hertfordshire Hospitals NHS Trust, Watford, UK
| | - G Bourner
- Laboratory Consultant, Guelph, ON, Canada
| | - A Merino
- Hemotherapy and Hemostasis Department, Hospital Clínic, Barcelona, Spain
| | - J-Y Han
- Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, South Korea
| | - Y Kawai
- Sanno Affiliate Hospital, International University of Health &Welfare, Tokyo, Japan
| | - M T Peng
- National Center for Clinical Laboratories (NCCL), Beijing, China
| | | | | |
Collapse
|
39
|
Yata M, Suzuki K, Furuhashi N, Kawakami K, Kawai Y, Naganawa S. Comparison of the multidetector-row computed tomography findings of IgG4-related sclerosing cholangitis and extrahepatic cholangiocarcinoma. Clin Radiol 2016; 71:203-10. [PMID: 26703117 DOI: 10.1016/j.crad.2015.10.024] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2015] [Revised: 08/30/2015] [Accepted: 10/20/2015] [Indexed: 01/13/2023]
Abstract
AIM To compare the multidetector-row computed tomography (MDCT) findings of IgG4-related sclerosing cholangitis (IgG4-SC) and extrahepatic cholangiocarcinoma (EH-CCA). MATERIALS AND METHODS Two radiologists who had no knowledge of the patients' clinical information retrospectively evaluated the CT findings of patients with IgG4-SC (n=33) and EH-CCA (n=39) on a consensus basis. Another radiologist measured the biliary lesions. IgG4-SC was diagnosed using the Japan Biliary Association criteria (2012) or the Mayo Clinic's HISORt criteria. EH-CCA was diagnosed based on surgical findings. RESULTS Compared with EH-CCA, IgG4-SC exhibited the following findings significantly more frequently: (a) wall thickening alone, (b) concentric wall thickening, (c) smooth inner margins, (d) homogeneous attenuation in the arterial phase, (e) a lesion involving the intrapancreatic bile duct, (f) smooth outer margins, (g) fully visible lumen, (h) a funnel-shaped proximal bile duct, (i) skip lesions, and (j) abnormal pancreatic findings. Conversely, (k) dual-layered attenuation in all phases was significantly more common in EH-CCA. The specificity values of parameters (e-k) were >80%. Regarding dimensions, (l) the biliary lesions were longer in IgG4-SC than in EH-CCA. (m) The diameters of the dilated proximal common bile duct and (n) the dilated proximal intrahepatic bile duct were smaller in IgG4-SC than in EH-CCA. CONCLUSION A number of CT findings are useful for differentiating between IgG4-SC and EH-CCA. CT findings (e-k) are particularly useful for this purpose.
Collapse
Affiliation(s)
- M Yata
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
| | - K Suzuki
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - N Furuhashi
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - K Kawakami
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Y Kawai
- Department of Diagnostic Radiology, Japanese Red Cross Nagoya Daiichi Hospital, 3-15 Michishita-cho, Nakamura-ku, Nagoya, Aichi 453-8511, Japan
| | - S Naganawa
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| |
Collapse
|
40
|
Hosonaga M, Sato E, Yamada K, Kaise H, Kimura F, Kawai Y, Ueda A, Teraoka S, Okazaki M, Ishikawa T. 69P Intratumoral heterogeneity of HER2 expression is associated with malignant biological behavior. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Yamada K, Kaise H, Hosonaga M, Kimura F, Kawai Y, Ueda A, Teraoka S, Okazaki M, Ishikawa T. 402P Efficacy of duloxetine for paclitaxel-induced and pregabalin-resistant peripheral neuropathy in Japanese breast cancer patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv531.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Ito F, Kobayashi H, Ito M, Mineta T, Kawai Y, Ohno T, Toyama H. Quantitative Analysis for Assessing the Post Therapeutic Hepatic Function Reserve by Using 99mTc-GSA SPECT. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
43
|
Kawai Y, Osawa T, Kobayashi K, Inoue R, Yamamoto Y, Matsumoto H, Nagao K, Hara T, Sakano S, Nagamori S, Matsuyama H. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer. Asian Pac J Cancer Prev 2015; 16:5687-90. [DOI: 10.7314/apjcp.2015.16.14.5687] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Yamaki S, Kawai Y, Yamazaki K. Characterization of a novel bacteriophage, Phda1, infecting the histamine-producing Photobacterium damselae
subsp. damselae. J Appl Microbiol 2015; 118:1541-50. [DOI: 10.1111/jam.12809] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 03/12/2015] [Accepted: 03/17/2015] [Indexed: 01/21/2023]
Affiliation(s)
- S. Yamaki
- Laboratory of Marine Food Science and Technology; Faculty of Fisheries Sciences; Hokkaido University; Minato Hakodate Japan
| | - Y. Kawai
- Laboratory of Marine Food Science and Technology; Faculty of Fisheries Sciences; Hokkaido University; Minato Hakodate Japan
| | - K. Yamazaki
- Laboratory of Marine Food Science and Technology; Faculty of Fisheries Sciences; Hokkaido University; Minato Hakodate Japan
| |
Collapse
|
45
|
Abstract
The presence of Epstein-Barr virus (EBV) DNA in biopsies of human tumors was tested by complementary RNA (cRNA) hybridization on membranes and DNA-DNA reassociation kinetics. DNA-DNA reassociation kinetics can detect as few as 1 EBV genome in every 50 cells, and the cRNA method can detect EBV genomes if 2 or more are present in a cell. Twenty-three out of 24 African Burkitt's lymphoma biopsies, 18 out of 23 African nasopharyngeal carcinomas (NPC), and 8 out of 24 other African tumors were positive for EBV DNA. Three cases of American Burkitt's lymphoma were tested by the cRNA method, and EBV DNA was not detected. Three out of 25 American tumors other than American Burkitt's lymphoma contained 0.1 to 0.3 genomes per cell of EBV DNA.
Collapse
|
46
|
Watanabe T, Nakada H, Takahashi T, Fujita K, Tanimoto Y, Sakae T, Kimoto S, Kawai Y. Potential for acceleration of bone formation after implant surgery by using a dietary supplement: an animal study. J Oral Rehabil 2015; 42:447-53. [PMID: 25572652 DOI: 10.1111/joor.12270] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/10/2014] [Indexed: 10/24/2022]
Abstract
Dental implant treatment is an effective modality to restore lost aesthetic and masticatory functions. However, healing after implant surgery takes at least 3-6 months. This prolonged healing period poses several difficulties for individuals with a large edentulous area and decreases their quality of life. Consequently, shortening the healing period and accelerating final prosthesis placement after surgery is very clinically important. Peri-implant bone formation may be enhanced by systemic approaches, such as the use of osteoporosis supplements, to promote bone metabolism. To confirm whether intake of a supplement developed for osteoporosis, synthetic bone mineral (SBM), was effective in accelerating peri-implant bone formation as part of the healing process after implantation. Twenty-four 5-week-old female Wistar rats were randomly assigned to receive a standardised diet without (control group, n = 12) or with SBM (n = 12). The rats had implant surgery at 8 weeks of age under general anaesthesia. The main outcome measures were bone mineral density (BMD) and pull-out strength in the implant and femur, which were compared between the groups at 2 and 4 weeks after implantation using the Mann-Whitney U test. BMD was significantly greater in the SBM group at 2 and 4 weeks after implantation compared to the control group. Pull-out strength was significantly greater in the SBM groups at 2 and 4 weeks after implantation compared to the control group. This study demonstrated that SBM could be effective in accelerating peri-implant bone formation during the healing period after implantation.
Collapse
Affiliation(s)
- T Watanabe
- Department of Removable Prosthodontics, Nihon University of Dentistry at Matsudo, Matsudo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Nishijima J, Hara T, Ikemoto K, Oga A, Kobayashi K, Kawai Y, Matsumoto H, Nagao K, Sasaki K, Gkoleizakis V, Fichtner J, Matsuyama H. Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer. Neoplasma 2015; 62:278-87. [PMID: 25591593 DOI: 10.4149/neo_2015_033] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED This study investigated differences in prevalence of the androgen-regulated transmembrane protease serine 2 (TMPRSS2) and ETS transcription factor family member, v-ets erythroblastosis virus E26 oncogene homolog (ERG) fusion gene (TMPRSS2-ERG fusions) in clinically localized prostate cancer Japanese and German patients. A total of 105 specimens, including 69 Japanese and 36 German patients, were collected. The status of TMPRSS2-ERG fusion was determined by fluorescence in situ hybridization, and correlations of the TMPRSS2-ERG fusion with clinicopathological characteristics and immunohistochemistry were studied. Gene fusions were identified in 20% (14/69) of Japanese and 53% (19/36) of German patients (P < 0.001). The difference in the type of gene fusion between the two ethnic groups was statistically significant (P=0.024). Overexpression of ERG protein was significantly associated with gene fusion. Biochemical recurrence was significantly higher in patients with ERG overexpression than in those without, and not related to TMPRSS2-ERG fusion status. Interestingly, two types of gene fusions (deletion and increase of copy number) were significantly associated with increased p53 expression (P = 0.005). Association of specific gene fusions harboring higher genomic alterations with p53 expression levels suggests that p53 mutation might drive more aggressive arrangements of TMPRSS2-ERG fusion in prostate cancer. KEYWORDS ERG, p53, prostate cancer, TMPRSS2-ERG fusion.
Collapse
|
48
|
Arakawa K, Matsunaga K, Takihiro S, Moritoki A, Ryuto S, Kawai Y, Masuda T, Miyamoto T. Lactobacillus gasseri requires peptides, not proteins or free amino acids, for growth in milk. J Dairy Sci 2014; 98:1593-603. [PMID: 25529420 DOI: 10.3168/jds.2014-8860] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Accepted: 11/02/2014] [Indexed: 11/19/2022]
Abstract
Lactobacillus gasseri is a widespread commensal lactic acid bacterium inhabiting human mucosal niches and has many beneficial effects as a probiotic. However, L. gasseri is difficult to grow in milk, which hurts usability for the food industry. It had been previously reported that supplementation with yeast extract or proteose peptone, including peptides, enables L. gasseri to grow well in milk. In this study, our objective was to confirm peptide requirement of L. gasseri and evaluate efficacy of peptide release by enzymatic proteolysis on growth of L. gassei in milk. Three strains of L. gasseri did not grow well in modified DeMan, Rogosa, Sharpe broth without any nitrogen sources (MRS-N), but addition of a casein-derived peptide mixture, tryptone, promoted growth. In contrast, little effect was observed after adding casein or a casein-derived amino acid mixture, casamino acids. These results indicate that L. gasseri requires peptides, not proteins or free amino acids, among milk-derived nitrogen sources for growth. Lactobacillus gasseri JCM 1131T hardly had growth capacity in 6 kinds of milk-based media: bovine milk, human milk, skim milk, cheese whey, modified MRS-N (MRSL-N) supplemented with acid whey, and MRSL-N supplemented with casein. Moreover, treatment with digestive proteases, particularly pepsin, to release peptides made it grow well in each milk-based medium. The pepsin treatment was the most effective for growth of strain JCM 1131T in skim milk among the tested food-grade proteases such as trypsin, α-chymotrypsin, calf rennet, ficin, bromelain, and papain. As well as strain JCM 1131T, pepsinolysis of milk improved growth of other L. gasseri strains and some strains of enteric lactobacilli such as Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus johnsonii, and Lactobacillus reuteri. These results suggest that some relatives of L. gasseri also use peptides as desirable nitrogen sources, and that milk may be a good supplier of nutritious peptides to enteric lactobacilli including L. gasseri after peptic digestion in the gastrointestinal tract. This is the first report showing peptide requirement of L. gasseri and efficacy of pepsinolysis on the growth of L. gasseri and its relatives in milk. This study would contribute to increasing usability of L. gasseri and its relatives as probiotics in dairy foods.
Collapse
Affiliation(s)
- K Arakawa
- Graduate School of Environmental and Life Science, Okayama University, Okayama 7008530, Japan
| | - K Matsunaga
- Graduate School of Environmental and Life Science, Okayama University, Okayama 7008530, Japan
| | - S Takihiro
- Graduate School of Environmental and Life Science, Okayama University, Okayama 7008530, Japan
| | - A Moritoki
- Graduate School of Environmental and Life Science, Okayama University, Okayama 7008530, Japan
| | - S Ryuto
- Graduate School of Environmental and Life Science, Okayama University, Okayama 7008530, Japan
| | - Y Kawai
- Graduate School of Bioresource Sciences, Nihon University, Kanagawa 2520880, Japan
| | - T Masuda
- Graduate School of Bioresource Sciences, Nihon University, Kanagawa 2520880, Japan
| | - T Miyamoto
- Graduate School of Environmental and Life Science, Okayama University, Okayama 7008530, Japan.
| |
Collapse
|
49
|
Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 2014; 29:2439-46. [PMID: 25047458 DOI: 10.1016/j.arth.2014.05.029] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 05/08/2014] [Indexed: 02/01/2023] Open
Abstract
Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000IU (20-mg) twice daily for 11-14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P=1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P=1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA.
Collapse
Affiliation(s)
- T Fuji
- Department of Orthopaedic Surgery, Japan Community Health care Organization Osaka Hospital, Osaka, Japan
| | - C-J Wang
- Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - S Fujita
- Department of Orthopedic Surgery, Takarazuka Daiichi Hospital, Hyogo, Japan
| | - Y Kawai
- International University of Health and Welfare, Tokyo, Japan
| | - T Kimura
- Clinical Planning Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan
| | | |
Collapse
|
50
|
Asahi Y, Tsujimoto I, Kawai Y, Sugimoto M, Suzuki T, Omichi S, Kogo M, Kotani J. General anaesthesia with and without intubation for patients with Cornelia de Lange syndrome. Southern African Journal of Anaesthesia and Analgesia 2014. [DOI: 10.1080/22201173.2009.10872614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|